Related Experiment Video
Updated: Jul 31, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Microbacterium spp. peritonitis in patients undergoing peritoneal dialysis: a single-center experience and literature
Xiao Yu1,2, Zhao Li1, Xinbo Yang2
1Department of Nephrology, Kidney Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Introduction:
Peritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is very rare, with only 9 cases reported to date. In this study, we report the treatment experiences of 7 patients at our peritoneal dialysis center.
Methods:
We retrospectively collected clinical characteristics and antibiotic management of all 7 episodes of PDRP caused by Microbacterium spp. in 7 patients from at our center over 4 years, and reviewed the documented Microbacterium spp. PDRP in the literature.
Results:
Empiric antibiotic therapy was initiated as soon as possible, and consisted of intraperitoneal (IP) gentamicin in combination with vancomycin. After up to 5 days, gentamicin was changed to meropenem if the treatment was not effective. The intended course of antibiotic treatment was 21-day. Totally, 6 episodes were cured (85.7%), which was higher than reported.
Conclusion:
The 21-day antibiotic therapy program by combining vancomycin and meropenem may benefit the management of Microbacterium spp. PDRP.
Insights
Peritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is rare. A 21-day antibiotic regimen combining vancomycin and meropenem shows promise for treating PDRP, with a high cure rate.
Area of Science:
- Nephrology
- Infectious Diseases
- Microbiology
Background:
- Peritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is an uncommon complication.
- Only 9 cases of Microbacterium spp. PDRP have been previously reported.
- This study details treatment experiences for 7 patients with Microbacterium spp. PDRP.
Purpose of the Study:
- To report treatment experiences of patients with Microbacterium spp. PDRP.
- To evaluate the effectiveness of a specific antibiotic regimen for Microbacterium spp. PDRP.
- To compare outcomes with previously reported cases.
Main Methods:
- Retrospective collection of clinical data and antibiotic management for 7 PDRP episodes caused by Microbacterium spp.
- Review of existing literature on Microbacterium spp. PDRP.
- Analysis of empiric and adjusted antibiotic therapy, including intraperitoneal (IP) gentamicin, vancomycin, and meropenem.
Main Results:
- Empiric therapy involved IP gentamicin and vancomycin, with gentamicin switched to meropenem if ineffective.
- The intended antibiotic course was 21 days.
- A total of 6 out of 7 episodes (85.7%) were cured, a higher rate than previously reported.
Conclusions:
- A 21-day antibiotic therapy combining vancomycin and meropenem may be beneficial for managing Microbacterium spp. PDRP.
- This treatment approach demonstrated a high cure rate in the studied patient cohort.
- Further research may validate this regimen for rare PDRP cases.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Microbiota of the Urogenital Tract

